February 1, 2019
Ono Pharmaceutical said on January 31 that it has grabbed rights in Asian regions, excluding mainland China, to develop and commercialize Canadian cancer biotech Repare Therapeutics’ first-in-class Pol-theta inhibitor. Under their strategic partnership, Ono will hold the rights to the...read more